Nuveen LLC Acquires Shares of 167,502 Oric Pharmaceuticals, Inc. $ORIC

Nuveen LLC purchased a new position in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 167,502 shares of the company's stock, valued at approximately $935,000. Nuveen LLC owned approximately 0.24% of Oric Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in Oric Pharmaceuticals by 34.0% in the 4th quarter. Bank of America Corp DE now owns 112,520 shares of the company's stock worth $908,000 after acquiring an additional 28,570 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Oric Pharmaceuticals by 16.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock valued at $5,788,000 after buying an additional 103,237 shares during the last quarter. Vivo Capital LLC raised its position in shares of Oric Pharmaceuticals by 62.8% in the first quarter. Vivo Capital LLC now owns 2,080,450 shares of the company's stock valued at $11,609,000 after buying an additional 802,632 shares during the last quarter. Sphera Funds Management LTD. raised its position in shares of Oric Pharmaceuticals by 112.8% in the fourth quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company's stock valued at $2,205,000 after buying an additional 144,817 shares during the last quarter. Finally, Two Sigma Advisers LP raised its position in shares of Oric Pharmaceuticals by 14.3% in the fourth quarter. Two Sigma Advisers LP now owns 66,500 shares of the company's stock valued at $537,000 after buying an additional 8,300 shares during the last quarter. Hedge funds and other institutional investors own 95.05% of the company's stock.

Oric Pharmaceuticals Trading Up 2.1%

NASDAQ:ORIC traded up $0.22 during mid-day trading on Wednesday, hitting $10.60. The stock had a trading volume of 1,178,720 shares, compared to its average volume of 711,086. The stock has a 50-day simple moving average of $10.39 and a two-hundred day simple moving average of $8.05. The company has a market capitalization of $1.03 billion, a PE ratio of -5.61 and a beta of 1.63. Oric Pharmaceuticals, Inc. has a twelve month low of $3.90 and a twelve month high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). Sell-side analysts predict that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ORIC shares. Wedbush reiterated an "outperform" rating and issued a $20.00 target price on shares of Oric Pharmaceuticals in a research report on Monday, June 23rd. Zacks Research upgraded shares of Oric Pharmaceuticals to a "hold" rating in a research report on Tuesday, August 12th. LADENBURG THALM/SH SH began coverage on shares of Oric Pharmaceuticals in a report on Tuesday, July 8th. They issued a "buy" rating and a $15.00 price objective for the company. Guggenheim reissued a "buy" rating and issued a $18.00 price objective on shares of Oric Pharmaceuticals in a report on Wednesday, August 13th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, August 14th. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Oric Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $17.63.

Insider Buying and Selling

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 32,466 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total transaction of $340,893.00. Following the sale, the chief financial officer owned 68,317 shares of the company's stock, valued at approximately $717,328.50. This trade represents a 32.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Angie You bought 26,597 shares of the business's stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of $9.39 per share, for a total transaction of $249,745.83. Following the completion of the acquisition, the director directly owned 26,597 shares in the company, valued at approximately $249,745.83. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have sold 40,000 shares of company stock worth $416,289. 5.55% of the stock is owned by corporate insiders.

Oric Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.